High-Dose Vitamin C Reprograms Immune Cells to Boost Pancreatic Cancer Immunotherapy

Pancreatic cancer remains one of the most lethal malignancies in the world, and one of the most stubbornly resistant to the immunotherapies that have transformed treatment for melanoma, lung cancer, and several other tumor types. Now, a new study published in Cancer Immunology, Immunotherapy suggests that an unexpectedly simple molecule, vitamin C, delivered at pharmacological doses, may help crack that resistance by reprogramming a critical population of immune cells inside the tumor itself. The research, led by a team at Beijing Friendship Hospital of Capital Medical University and collaborators, provides mechanistic evidence that high-dose vitamin C can push tumor-associated macrophages toward an anti-tumor state and, in doing so, make PD-1 blockade therapy work better in mouse models of pancreatic cancer.

The study focused on tumor-associated macrophages, or TAMs, which are among the most abundant immune cells in the pancreatic tumor microenvironment. Macrophages are remarkably plastic cells: depending on the signals they receive, they can polarize toward an M1-like state, which produces inflammatory signals such as tumor necrosis factor-alpha, interleukin-6, interleukin-1 beta, and inducible nitric oxide synthase, and which supports the activation of cytotoxic T cells. Alternatively, they can drift toward an M2-like state, which suppresses immune responses, promotes tissue remodeling, and helps tumors evade destruction. In pancreatic cancer, the balance is heavily tilted toward the immunosuppressive M2-like phenotype, contributing to the tumors’ well-deserved reputation as immunological fortresses that checkpoint inhibitors alone rarely penetrate.

High-dose vitamin C has attracted growing scientific interest over the past decade. Unlike the modest dietary amounts obtained from fruit and vegetables, pharmacological doses of ascorbate, typically delivered intravenously, achieve blood concentrations far above what oral supplementation can reach. At these levels, vitamin C can act as a pro-oxidant in the tumor microenvironment, generating hydrogen peroxide and imposing metabolic stress on cancer cells, while also exerting immunomodulatory effects on various immune cell populations. Previous work has hinted at antitumor activity in several cancer models, but whether the molecule could reshape the macrophage landscape of pancreatic tumors, and what signaling pathways might be responsible, remained unclear.

To address these questions, the researchers evaluated high-dose vitamin C in a subcutaneous KPC mouse model, a widely used preclinical system that recapitulates key features of pancreatic ductal adenocarcinoma. The results were striking: treatment with high-dose vitamin C significantly inhibited pancreatic tumor growth and prolonged survival in the animals. This established that the intervention had genuine antitumor activity in vivo, but the more important question was how it achieved that effect, and whether the immune system was involved.

To dissect the mechanism, the team turned to in vitro models using mouse and human macrophages stimulated with lipopolysaccharide and interferon-gamma, a combination that reliably drives macrophages toward the M1 phenotype. When vitamin C was added to this stimulation, it markedly enhanced M1 polarization, boosting the expression of classic M1 markers and inflammatory mediators. Crucially, the treatment did not markedly increase M2-associated features, meaning the effect was a genuine push toward the anti-tumor state rather than a nonspecific perturbation of macrophage biology. The finding was consistent across both mouse bone marrow-derived macrophages and human macrophage models, suggesting the phenomenon is not a species-specific quirk.

The molecular machinery behind this effect was probed with a battery of complementary techniques, including RNA sequencing, western blotting, flow cytometry, pharmacological inhibition, and siRNA-mediated knockdown. These experiments converged on the JAK2-STAT1 signaling pathway, a canonical inflammatory axis through which interferon-gamma exerts many of its effects on macrophages. Vitamin C treatment increased the phosphorylation, and therefore the activation, of both JAK2 and STAT1. When the researchers blocked this pathway, either with pharmacological inhibitors or by silencing JAK2 with siRNA, the ability of vitamin C to enhance M1 polarization was substantially diminished. This places JAK2-STAT1 activation at the center of the mechanism, positioning vitamin C as an amplifier of the very interferon-driven signals that define pro-inflammatory macrophage identity.

Perhaps the most persuasive piece of evidence came from the macrophage depletion experiments. When the researchers depleted macrophages in vivo using clodronate liposomes, a standard technique in which lipid vesicles containing the toxic drug clodronate are engulfed and destroy macrophages, the antitumor efficacy of high-dose vitamin C was markedly attenuated. In other words, without macrophages present, vitamin C largely lost its ability to fight the tumors. This experiment provides strong causal support for the idea that the benefit of vitamin C in this setting depends on macrophage-centered immune modulation, rather than on direct tumor cell killing alone, even though direct cytotoxic mechanisms of pharmacological ascorbate are well documented in other contexts.

The study then moved to the clinically most consequential question: whether vitamin C could improve the performance of immune checkpoint inhibitors in pancreatic cancer. Anti-PD-1 antibodies, which unleash T cells by blocking the programmed cell death protein 1 brake on their surface, have produced disappointing results in pancreatic cancer as monotherapy, in large part because the tumor microenvironment lacks the pre-existing T cell activity that PD-1 blockade requires. In the KPC model, combining high-dose vitamin C with anti-PD-1 therapy enhanced treatment efficacy compared with either approach alone. The combination was accompanied by increased numbers of M1-like macrophages and greater infiltration of CD8-positive cytotoxic T cells into the tumor microenvironment, painting a picture in which vitamin C-conditioned macrophages help create the inflammatory context that allows checkpoint blockade to recruit and activate tumor-killing T cells.

The implications of this work extend beyond pancreatic cancer, although the disease remains the most urgent beneficiary. Pancreatic ductal adenocarcinoma is projected to become one of the leading causes of cancer death in the coming decades, and the near-total failure of immunotherapy in this tumor type has made combination strategies a central research priority. The study offers a mechanistically grounded rationale for pairing pharmacological vitamin C with checkpoint inhibitors, a combination that is comparatively inexpensive and has a well-characterized safety profile at appropriate doses. It also adds to a broader shift in oncology research: rather than targeting tumor cells exclusively, many of the most promising new strategies aim to reprogram the stromal and immune cells that tumors co-opt for their own protection.

At the same time, the researchers and the field at large are careful to note the distance between mouse models and human patients. The findings come from subcutaneous KPC models and in vitro macrophage systems, and the authors themselves frame the work as providing a rationale for further investigation rather than an established treatment strategy. Clinical trials will be needed to determine whether the macrophage-reprogramming effects observed in mice translate to human pancreatic tumors, what dosing regimens are optimal, and how vitamin C-based combinations should be sequenced with existing chemotherapy and immunotherapy. Still, for a disease with so few options and such a desperate need for new ideas, the demonstration that a simple vitamin can flip macrophages from tumor allies into tumor attackers, through a defined JAK2-STAT1 mechanism, and thereby unlock the potential of PD-1 blockade, is the kind of result that could reshape how the field thinks about the immunosuppressive tumor microenvironment. The study, published open access on 13 October 2026, was supported by funding from the National Key Technologies R&D Program, the National Natural Science Foundation of China, and other Chinese research programs, and was conducted under protocols approved by the institutional animal care committee of Beijing Friendship Hospital.

Subject of Research: High-dose vitamin C modulation of tumor-associated macrophage polarization and anti-PD-1 immunotherapy efficacy in pancreatic cancer

Article Title: High-dose vitamin C augments LPS/IFN-γ-induced M1 macrophage polarization through JAK2-STAT1 activation and promotes anti-PD-1 efficacy in pancreatic cancer

Article References: Zhao, H., Fu, W., Zhang, W., Li, X., Zhang, T., Yao, H., & Zhang, Z. (2026). High-dose vitamin C augments LPS/IFN-γ-induced M1 macrophage polarization through JAK2-STAT1 activation and promotes anti-PD-1 efficacy in pancreatic cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04592-9

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04592-9

Keywords: pancreatic cancer, high-dose vitamin C, tumor-associated macrophages, M1 macrophage polarization, JAK2-STAT1 pathway, anti-PD-1 therapy, immune checkpoint inhibitors, tumor microenvironment, CD8-positive T cells, cancer immunotherapy, KPC mouse model, immunomodulation